Yelena Y. Janjigian, Hanneke W.M. van Laarhoven, Roy Rabbie, Caron Lloyd, Zhuoer Sun, Jeeyun Lee. "First-line (1L) trastuzumab deruxtecan (T-DXd) with volrustomig and fluoropyrimidine in patients with HER2-low gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): DESTINY-Gastric03 (DG-03) part 5.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.2_suppl.tps472